Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360602 | 1.00 | JAK2 (0.41) | JAK2JAK3PTK2KDRTNIK | |
| SCHEMBL30360613 | 0.90 | PIK3CA (0.41) | JAK2JAK3PTK2KDRTNIK | |
| SCHEMBL26516659 | 0.90 | PIK3CA (0.41) | JAK2JAK3PTK2KDRTNIK | |
| SCHEMBL26516654 | 0.88 | CCR2 (0.41) | JAK2JAK3PTK2KDRTNIK | |
| SCHEMBL26119124 | 0.87 | CCR2 (0.47) | JAK2JAK3PTK2CCR2 | |
| SCHEMBL26119662 | 0.87 | OPRM1 (0.41) | JAK2JAK3PTK2KDRTNIK | |
| SCHEMBL26516660 | 0.86 | GPR119 (0.44) | JAK2JAK3PTK2KDR | |
| Ammonia Solution, Strong SCHEMBL29006622 | 0.80 | LRRK2 (0.35) | CCR2GHSRPTGS2 | |
| SCHEMBL29006626 | 0.78 | MAP4K1 (0.47) | JAK2JAK3PTK2PTGS2 | |
| SCHEMBL26123679 | 0.77 | MAP4K4 (0.39) | TNIKPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | JAK2 28/4885JAK3 456/4885PTK2 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.